- Telehealth Visits
- Insurance plan information
Mwanasha Hamuza Merrill, MD
Medical Oncology • Hematology- Telehealth Visits
- Insurance plan information
Mwanasha Hamuza Merrill, MD
Medical Oncology • Hematology- Telehealth Visits
- Insurance plan information
On this page
About me
Mwanasha Hamuza Merrill is a hematologist-oncologist who cares for patients with blood cancers, including non-Hodgkin's lymphomas, Hodgkin's lymphomas and other lymphoproliferative diseases (those causing uncontrolled production of the white blood cells called lymphocytes).
In her research, Merrill focuses on advancing personalized treatments for people with B-cell lymphoma (the most common type) and T-cell lymphoma (a rare type). She is also interested in developing diagnostic tools to improve the speed and accuracy of lymphoma diagnosis for individuals in low- and middle-income countries who may lack access to advanced medical care.
Merrill earned her medical degree from Tufts University. She completed a residency in internal medicine at Beth Israel Deaconess Medical Center, followed by a fellowship in hematology-oncology at Dana-Farber Cancer Institute and Mass General Brigham.
Education & training
Board certification
- Hematology, American Board of Internal Medicine/Hematology
- Medical Oncology, American Board of Internal Med/Medical Oncology
- Internal Medicine, American Board of Internal Medicine
Degree
- MD, Tufts University School of Medicine
My expertise
Specialties
Locations
Clinical Trials query: q=health_gateway_id_ss%3A%28%225045%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%225045%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.